The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Atropisomerism in Medicinal Chemistry: Challenges and Opportunities
Open accessAbstract
Atropisomerism is a dynamic type of axial chirality that is ubiquitous in medicinal chemistry. There are several examples of stable atropisomeric US FDA-approved drugs and experimental compounds, and in each case the atropisomers of these compounds possess drastically different biological activities. Rapidly interconverting atropisomerism is even more prevalent, and while such compounds are typically considered achiral, they bind their protein targets in an atroposelective fashion, with the nonrelevant atropisomer contributing little to the desired activities. It has been recently demonstrated that various properties of an interconverting atropisomer can be modulated through the synthesis of atropisomer stable and pure analogs. Herein we discuss examples of atropisomerism in drug discovery as well as challenges and opportunities moving forward.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Watterson, K. R., Bestow, D., Gallagher, J., Hamilton, D. L., Ashford, F. B., Meakin, P. J., & Ashford, M. L. J. (2013) · Neurosignals · doi:10.1159/000334144 · Cited by 3,389
The Medicinal Chemist’s Toolbox: An Analysis of Reactions Used in the Pursuit of Drug Candidates
Roughley, S. D., & Jordan, A. M. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200187y · Cited by 2,725
The selectivity of protein kinase inhibitors: a further update
Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., Mclauchlan, H., Klevernic, I., Arthur, J. S. C., Alessi, D. R., & Cohen, P. (2007) · Biochemical Journal · doi:10.1042/bj20070797 · Cited by 2,520
Comprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
Protein kinases — the major drug targets of the twenty-first century?
Cohen, P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd773 · Cited by 2,186
DrugBank 4.0: shedding new light on drug metabolism
Law, V., Knox, C., Djoumbou, Y., Jewison, T., Guo, A. C., Liu, Y., Maciejewski, A., Arndt, D., Wilson, M., Neveu, V., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1068 · Cited by 1,993
Brown, D. G., & Boström, J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01409 · Cited by 1,964
Atroposelective Total Synthesis of Axially Chiral Biaryl Natural Products
Bringmann, G., Gulder, T., Gulder, T. A. M., & Breuning, M. (2010) · Chemical Reviews · doi:10.1021/cr100155e · Cited by 1,458
The exploration of macrocycles for drug discovery — an underexploited structural class
Driggers, E. M., Hale, S. P., Lee, J., & Terrett, N. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2590 · Cited by 1,370
Rational design of inhibitors that bind to inactive kinase conformations
Liu, Y., & Gray, N. S. (2006) · Nature Chemical Biology · doi:10.1038/nchembio799 · Cited by 1,094
Profound Methyl Effects in Drug Discovery and a Call for New CH Methylation Reactions
Schönherr, H., & Cernak, T. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201303207 · Cited by 1,094
Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy
Kang, M. H., & Reynolds, C. P. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0144 · Cited by 1,016
FDA-approved small-molecule kinase inhibitors
Wu, P., Nielsen, T. E., & Clausen, M. H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.005 · Cited by 1,013
Solca, F., Dahl, G., Zoephel, A., Bader, G., Sanderson, M., Klein, C., Kraemer, O., Himmelsbach, F., Haaksma, E., & Adolf, G. R. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.197756 · Cited by 865
Assessing Atropisomer Axial Chirality in Drug Discovery and Development
LaPlante, S. R., Fader, L. D., Fandrick, K. R., Fandrick, D. R., Hucke, O., Kemper, R., Miller, S. P. F., & Edwards, P. J. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200584g · Cited by 861
The promise and peril of chemical probes
Arrowsmith, C. H., Audia, J. E., Austin, C., Baell, J., Bennett, J., Blagg, J., Bountra, C., Brennan, P. E., Brown, P. J., Bunnage, M. E., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1867 · Cited by 839
The Challenge of Atropisomerism in Drug Discovery
Clayden, J., Moran, W. J., Edwards, P. J., & LaPlante, S. R. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200901719 · Cited by 783
Kumarasamy, E., Raghunathan, R., Sibi, M. P., & Sivaguru, J. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00136 · Cited by 756
Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
Liu, Q., Sabnis, Y., Zhao, Z., Zhang, T., Buhrlage, S. J., Jones, L. H., & Gray, N. S. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.12.006 · Cited by 652
Revealing Atropisomer Axial Chirality in Drug Discovery
LaPlante, S. R., Edwards, P. J., Fader, L. D., Jakalian, A., & Hucke, O. (2011) · ChemMedChem · doi:10.1002/cmdc.201000485 · Cited by 535
Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors
Cohen, M. S., Zhang, C., Shokat, K. M., & Taunton, J. (2005) · Science · doi:10.1126/science1108367 · Cited by 506
Dynamic Kinetic Resolution of Biaryl Atropisomers via Peptide-Catalyzed Asymmetric Bromination
Gustafson, J. L., Lim, D., & Miller, S. J. (2010) · Science · doi:10.1126/science.1188403 · Cited by 461
Self-citationSteric effects. A study of a rationally designed system
Bott, G., Field, L. D., & Sternhell, S. (1980) · Journal of the American Chemical Society · doi:10.1021/ja00537a036 · Cited by 393
Kinase Drug Discovery – What’s Next in the Field?
Cohen, P., & Alessi, D. R. (2013) · ACS Chemical Biology · doi:10.1021/cb300610s · Cited by 377
Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks
Barf, T., & Kaptein, A. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3003203 · Cited by 331
Pharmacological PKA Inhibition: All May Not Be What It Seems
Murray, A. J. (2008) · Science Signaling · doi:10.1126/scisignal.122re4 · Cited by 327
Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain
Knowles, P. P., Murray-Rust, J., Kjær, S., Scott, R. P., Hanrahan, S., Santoro, M., Ibáñez, C. F., & McDonald, N. Q. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605604200 · Cited by 302
Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization.
Okamoto, K., Ikemori-Kawada, M., Jestel, A., von König, K., Funahashi, Y., Matsushima, T., Tsuruoka, A., Inoue, A., & Matsui, J. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500394m · Cited by 285
Structural basis for selective inhibition of Src family kinases by PP1
Liu, Y., Bishop, A., Witucki, L., Kraybill, B., Shimizu, E., Tsien, J., Ubersax, J., Blethrow, J., Morgan, D. O., & Shokat, K. M. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(99)80118-5 · Cited by 252
Tanaka, K., Takeishi, K., & Noguchi, K. (2006) · Journal of the American Chemical Society · doi:10.1021/ja060348f · Cited by 247
Chemical Genetics: Where Genetics and Pharmacology Meet
Knight, Z. A., & Shokat, K. M. (2007) · Cell · doi:10.1016/j.cell.2007.01.021 · Cited by 243
Diener, M. E., Metrano, A. J., Kusano, S., & Miller, S. J. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b07726 · Cited by 222
Biological Stereoselectivity of Atropisomeric Natural Products and Drugs
Zask, A., Murphy, J., & Ellestad, G. A. (2013) · Chirality · doi:10.1002/chir.22145 · Cited by 217
Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2
Foster, S. A., Whalen, D. M., Özen, A., Wongchenko, M. J., Yin, J., Yen, I., Schaefer, G., Mayfield, J. D., Chmielecki, J., Stephens, P. J., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.010 · Cited by 212
Hanson, S. M., Morlock, E. V., Satyshur, K. A., & Czajkowski, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800889m · Cited by 204
Targeted covalent drugs of the kinase family
Singh, J., Petter, R. C., & Kluge, A. F. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.06.168 · Cited by 177
Cardiotoxicity Associated with Targeting Kinase Pathways in Cancer
Mellor, H. R., Bell, A. R., Valentin, J.-P., & Roberts, R. R. A. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfq378 · Cited by 168
Multiple Conformations of Phosphodiesterase-5
Wang, H., Liu, Y., Huai, Q., Cai, J., Zoraghi, R., Francis, S. H., Corbin, J. D., Robinson, H. H., Xin, Z., Lin, G., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512527200 · Cited by 167
Enantioselective Synthesis of Atropisomeric Benzamides through Peptide-Catalyzed Bromination
Barrett, K. T., & Miller, S. J. (2013) · Journal of the American Chemical Society · doi:10.1021/ja400082x · Cited by 158
Watterson, S. H., Lucca, G. V. D., Shi, Q., Langevine, C. M., Liu, Q., Batt, D. G., Bertrand, M. B., Gong, H., Dai, J., Yip, S. H., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01088 · Cited by 155
Levinson, N. M., & Boxer, S. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029828 · Cited by 149
Tetrahydroisoquinoline amide substituted phenyl pyrazoles as selective Bcl-2 inhibitors
Porter, J. R., Payne, A., de Candole, B., Ford, D., Hutchinson, B., Trevitt, G. P., Turner, J., Edwards, C., Watkins, C., Whitcombe, I. W. A., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.10.113 · Cited by 125
Jacques, V., Czarnik, A. W., Judge, T. M., der Ploeg, L. H. T. V., & DeWitt, S. H. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417832112 · Cited by 113
Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib
Capdevila, J., & Stjepanovic, N. (2014) · Biologics: Targets and Therapy · doi:10.2147/btt.s39381 · Cited by 85
Exploiting Atropisomerism to Increase the Target Selectivity of Kinase Inhibitors
Smith, D. E., Marquez, I., Lokensgard, M. E., Rheingold, A. L., Hecht, D., & Gustafson, J. L. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201506085 · Cited by 71
Self-citationLeivers, A. L., Tallant, M. D., Shotwell, J. B., Dickerson, S. H., Leivers, M. R., McDonald, O. B., Gobel, J., Creech, K. L., Strum, S. L., Mathis, A., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400781h · Cited by 71
Concise and Practical Asymmetric Synthesis of a Challenging Atropisomeric HIV Integrase Inhibitor
Fandrick, K. R., Li, W., Zhang, Y., Tang, W., Gao, J., Rodriguez, S., Patel, N. D., Reeves, D. C., Wu, J., Sanyal, S., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201501575 · Cited by 66
Schoenherr, H., & Cernak, T. (2014) · ChemInform · doi:10.1002/chin.201405245 · Cited by 55
Cornelison, M., Jabbour, E. J., & Welch, M. A. (2012) · The Journal of Supportive Oncology · doi:10.1016/j.suponc.2011.08.001 · Cited by 50
LaPlante, S. R., Forgione, P., Boucher, C., Coulombe, R., Gillard, J. R., Hucke, O., Jakalian, A., Joly, M., Kukolj, G., Lemke, C. T., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401202a · Cited by 45
Cisar, J. S., Ferreras, J. A., Soni, R. K., Quadri, L. E. N., & Tan, D. S. (2007) · Journal of the American Chemical Society · doi:10.1021/ja0721521 · Cited by 44
Concise and Practical Asymmetric Synthesis of a Challenging Atropisomeric HIV Integrase Inhibitor
Fandrick, K. R., Li, W., Zhang, Y., Tang, W., Gao, J., Rodríguez, S., Patel, N. D., Reeves, D. C., Wu, J., Sanyal, S., et al. (2015) · Angewandte Chemie · doi:10.1002/ange.201501575 · Cited by 41
Exploiting Atropisomerism to Increase the Target Selectivity of Kinase Inhibitors
Smith, D. E., Marquez, I., Lokensgard, M. E., Rheingold, A. L., Hecht, D., & Gustafson, J. L. (2015) · Angewandte Chemie · doi:10.1002/ange.201506085 · Cited by 40
Self-citationNew Frontiers in Kinases: Second Generation Inhibitors
Laufer, S., & Bajorath, J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500195x · Cited by 24
Ichikawa, M., Yokomizo, A., Itoh, M., Haginoya, N., Sugita, K., Usui, H., Terayama, K., & Kanda, A. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.07.007 · Cited by 23
Synthesis, SAR, and atropisomerism of imidazolopyrimidine DPP4 inhibitors
O’Connor, S. P., Wang, Y., Simpkins, L. M., Brigance, R. P., Meng, W., Wang, A., Kirby, M., Weigelt, C. A., & Hamann, L. G. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.08.090 · Cited by 22
Cited by
Atropisomerism in the Pharmaceutically Relevant Realm
Basilaia, M., Chen, M. H., Secka, J., & Gustafson, J. L. (2022) · Accounts of Chemical Research · doi:10.1021/acs.accounts.2c00500 · Cited by 326
Self-citationChirality of New Drug Approvals (2013–2022): Trends and Perspectives
McVicker, R. U., & O’Boyle, N. M. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02239 · Cited by 255
Metadata
- Authors
- Toenjes, S. T., & Gustafson, J. L.
- Venue
- Future Medicinal Chemistry
- Publisher
- Informa UK Limited
- Published
- 2018-01-30
- Volume
- 10
- Issue
- 4
- Pages
- 409-422
- ISSN
- 1756-8919 (ISSN-L)
- 1756-8927
- OpenAlex
- W2786849322
- Cited by
- 382
- References
- 57
- FWCI
- 9.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.